Alvorlige infektioner, der som minimum muligvis var relateret til behandling, rapporteredes hos 1, 8% af de abataceptbehandlede patienter og hos 1, 0% af de placebobehandlede.
Serious infections at least possibly related to treatment were reported in 1.8% of abatacept-treated patients and 1.0% of placebo-treated patients.